Skip to Main Content
RegisterSign-in
Home
  • Connect with us on Facebook
  • Follow us on Twitter
  • See our video channel on Youtube
  • Subsribe to our RSS feed
  • View our images on Flickr
  • Home
  • Latest Advances
    • Publications
    • News
    • Tell us your thoughts
    • Photo Gallery
    • Video Gallery
  • Development Phases
    • Basic Science
    • Clinical Development
    • Regulatory
    • Venture Capital
    • Exit Partners
  • Events
  • For Patients
    • Forums
    • Product Reviews
  • About
  • Contact
  • Partners

How do you see the OPI index being integrated into an FDA submission?

The Inaugural Dry Eye Summit 2010 Section: Lessons Learned in the Dry Eye Application Process
  • Main-tags:
    • Clinical Development,
    • Regulatory
  • Sub-tags:
    • Wiley Chambers,
    • Stephen Pflugfelder,
    • OPI,
    • Mark B Abelson,
    • Jerry Cagle,
    • George Ousler,
    • FDA
  • Video tags:
    • Dry Eye Summit 2010,
    • Lessons Learned

Related Videos

  • Have topical agents or systemic drugs been used to treat dry eye?
  • What do we know about the enervation of the meibomian gland? What regulates MG lipid secretion?
  • Is MGD part of the differential diagnosis of dry eye or at the core of dry eye?
  • What is the effect of dry eye chamber patient selection on labeling language for drug indications?
  • How do Dry Eye chamber results correlate from mice to humans?
  • What is the value of quality of life questionnaires in dry eye studies?
  • Is mean change from baseline in a sign or symptom an acceptable endpoint for primary approval?
  • What endpoints might be appropriate for studying a neurotrophy dry eye product candidate?
  • Is OPI a validated endpoint? How it might be used towards an FDA approval?
  • Lessons Learned in the Dry Eye Application Process - Panel Introduction

  • All authors
  • Contact us
  • Account
© 2011, Dry Eye Summit.